Six Drugs Added to Knowledgebase

We recently added six new drugs to the knowledgebase:

• Exebacase an antistaphylococcal lysin for the treatment of complicated S. aureus bacteremia is being developed by ContraFect
• Treosulfan an alkylating agent for the treatment of allogeneic hematopoietic stem cell transplantation (allo-HSCT) is being developed by Medexus Pharmaceuticals and Medac
• Litifilimab an anti-BDCA2 antibody for the treatment of lupus erythematosus and cutaneous lupus erythematosus is being developed by Biogen
• Garadacimab a factor XIIa-inhibitory monoclonal antibody (FXIIa mAb) for the treatment of hereditary angioedema (HAE) is being developed by CSL
• Fesomersen an antisense drug for the treatment of thrombosis prophylaxis is being developed by Ionis Pharmaceuticals and Bayer
• Aumolertinib an EGFR-tyrosine kinase inhibitor for the treatment of EGFR-mutated non-small cell lung cancer (NSCLC) is being developed by EQRx and Jiangsu Hansoh Pharmaceutical
  

The Prescribe Right Pharmaceutical Pipeline Tracker now allows you to track 1,060 investigational and recently approved drugs supported by 2,716 announced and published study results.